Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)
China · Delayed Price · Currency is CNY 22.03
-0.01 (-0.05%)
Aug 31, 2026, 3:04 PM CST
SHE:002262 Revenue
Jiangsu Nhwa Pharmaceutical Co., LTD had revenue of 1.61B CNY in the quarter ending June 30, 2026, with 7.25% growth. This brings the company's revenue in the last twelve months to 6.12B, up 2.94% year-over-year. In the year 2025, Jiangsu Nhwa Pharmaceutical Co., LTD had annual revenue of 5.91B with 3.75% growth.
Revenue (ttm)
6.12B
Revenue Growth
+2.94%
P/S Ratio
3.66
Revenue / Employee
1.02M
Employees
6,003
Market Cap
22.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.91B | 213.56M | 3.75% |
| Dec 31, 2024 | 5.70B | 656.13M | 13.01% |
| Dec 31, 2023 | 5.04B | 742.99M | 17.28% |
| Jan 1, 2023 | 4.30B | 362.85M | 9.22% |
| Jan 1, 2022 | 3.94B | 574.36M | 17.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harbin Pharmaceutical Group | 16.14B |
| Livzon Pharmaceutical Group | 10.75B |
| Apeloa Pharmaceutical Co.,Ltd | 9.16B |
| Tasly Pharmaceutical Group | 8.15B |
| Hubei Jumpcan Pharmaceutical | 5.80B |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 4.72B |
| Betta Pharmaceuticals | 3.85B |
| Jilin Aodong Pharmaceutical Group | 2.23B |
Jiangsu Nhwa Pharmaceutical Co., LTD News
- 13 days ago - Jiangsu Nhwa Pharmaceutical Co., LTD Quarterly report: Q2 2026 - Filings
- 4 months ago - Jiangsu Nhwa Pharmaceutical Co., LTD Annual report: H2 2025 - Filings
- 4 months ago - Jiangsu Nhwa Pharmaceutical Co., LTD Quarterly report: Q1 2026 - Filings
- 8 months ago - Luye Pharma Grants Nhwa Rights To Commercialize Three LAI Antipsychotics In Chinese Mainland - Nasdaq
- 11 months ago - Jiangsu Nhwa Pharmaceutical Co., LTD Quarterly report: Q3 2025 - Filings